Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03372161 · ClinicalTrials.gov registry record · Phase 3
Corticosteroid Lumbar Epidural Analgesia for Radiculopathy
A Phase 3 study of Lumbosacral Radicular Pain, sponsored by Scilex Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 401
- Enrollment target
- 20
- Study locations
NCT03372161 is a Phase 3 study of Lumbosacral Radicular Pain that has completed, run by Scilex Pharmaceuticals. The registered enrollment target is 401 participants. The trial reports 20 study locations across 7 states.
The verdict
NCT03372161, a Phase 3 study of Lumbosacral Radicular Pain, has completed, sponsored by Scilex Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 401 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a research study of SP-102, an experimental medication designed to relieve pain in patients with a specific type of leg pain. The medication is given once by your healthcare professional, with a possibility of a second injection as early as about 1 month after the first treatment. The purpose of the study is to measure how well a single injection of the experimental medication, SP-102, relieves pain. The study will also investigate the side effects of SP-102.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SP-102
Study Locations (20)
Florida
- Semnur Research Site 56 - Fernandina Beach
- Semnur Research Site 81 - Jacksonville
- Semnur Research Site 49 - St. Petersburg
- Semnur Research Site 13 - Tampa
- Semnur Research Site 61 - Tampa
- Semnur Research Site 53 - Winter Park
Illinois
- Semnur Research Site 40 - Bloomington
- Semnur Research Site 63 - Chicago
- Semnur Research Site 12 - Chicago
- Semnur Research Site 19 - Chicago
California
- Semnur Research Site 18 - La Jolla
- Semnur Research Site 47 - Laguna Woods
- Semnur Research Site 70 - Los Gatos
Georgia
- Semnur Research Site 28 - Marietta
- Semnur Research Site 64 - Marietta
- Semnur Research Site 10 - Newnan
Arizona
- Semnur Research Site 52 - Phoenix
- Semnur Research Site 58 - Tempe
Alabama
- Semnur Research Site 75 - Mobile
Idaho
- Semnur Research Site 38 - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 401 participants |
| Start Date | 2017-12-08 |
| Est. Completion | 2022-01-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03372161
The ClinicalTrials.gov registry entry for NCT03372161 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 401 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Scilex Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lumbosacral Radicular Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03372161 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, Illinois, California.
Frequently Asked Questions
What is clinical trial NCT03372161 about?
NCT03372161 is a clinical study titled "Corticosteroid Lumbar Epidural Analgesia for Radiculopathy". This is a research study of SP-102, an experimental medication designed to relieve pain in patients with a specific type of leg pain. The medication is given once by your healthcare professional, with a possibility of a second injection as early as about 1 month after the first treatment. The purpo...
What is the current status of trial NCT03372161?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 401 participants. The study started on 2017-12-08. Estimated completion is 2022-01-06.
What conditions does trial NCT03372161 study?
This clinical trial studies the following conditions: Lumbosacral Radicular Pain.
What interventions are being tested in trial NCT03372161?
The interventions under investigation include: Placebo (DRUG), SP-102 (DRUG).
Who is sponsoring clinical trial NCT03372161?
This trial is sponsored by Scilex Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03372161 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.